SHP-2 is recognized as a promising drug target for the treatment of multiple cancer types and tumors, including leukemia, Noonan syndrome (NS), LEOPARD syndrome (LS), colon cancer, melanoma, lung adenocarcinoma, neuroblastoma, and hepatocellular carcinoma [53,54,55]. This evidence concerns the gene PTPN11 and cancer.